Where this LCD applies
Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.
| Contract | Contractor | Type | States |
|---|---|---|---|
| 09101 | First Coast Service Options, Inc. | A and B MAC | FL |
| 09201 | First Coast Service Options, Inc. | A and B MAC | PR VI |
| 09102 | First Coast Service Options, Inc. | A and B MAC | FL |
| 09202 | First Coast Service Options, Inc. | A and B MAC | PR |
| 09302 | First Coast Service Options, Inc. | A and B MAC | VI |
Billing and coding article A57678: diagnoses and procedure codes
Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A57678 (Billing and Coding: Allergen Immunotherapy) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.
Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.
A57678: Billing and Coding: Allergen Immunotherapy (Billing and Coding, effective 2025-10-01)
- Covered ICD-10-CM codes
- 128
- 3 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 11
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| H10.411 | Chronic giant papillary conjunctivitis, right eye |
| H10.412 | Chronic giant papillary conjunctivitis, left eye |
| H10.413 | Chronic giant papillary conjunctivitis, bilateral |
| H10.45 | Other chronic allergic conjunctivitis |
| J30.0 | Vasomotor rhinitis |
| J30.1 | Allergic rhinitis due to pollen |
| J30.2 | Other seasonal allergic rhinitis |
| J30.81 | Allergic rhinitis due to animal (cat) (dog) hair and dander |
| J30.89 | Other allergic rhinitis |
| J31.0 | Chronic rhinitis |
| J45.20 | Mild intermittent asthma, uncomplicated |
| J45.30 | Mild persistent asthma, uncomplicated |
| J45.40 | Moderate persistent asthma, uncomplicated |
| J45.50 | Severe persistent asthma, uncomplicated |
| T36.0X5A | Adverse effect of penicillins, initial encounter |
| T36.0X5D | Adverse effect of penicillins, subsequent encounter |
| T36.0X5S | Adverse effect of penicillins, sequela |
| T36.1X5A | Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter |
| T36.1X5D | Adverse effect of cephalosporins and other beta-lactam antibiotics, subsequent encounter |
| T36.1X5S | Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela |
| T36.4X5A | Adverse effect of tetracyclines, initial encounter |
| T36.4X5D | Adverse effect of tetracyclines, subsequent encounter |
| T36.4X5S | Adverse effect of tetracyclines, sequela |
| T36.8X5A | Adverse effect of other systemic antibiotics, initial encounter |
Procedure codes: 95115, 95117, 95144, 95145, 95146, 95147, 95148, 95149, 95165, 95170, 95180.
Coverage indications, limitations and medical necessity
Compliance with the provisions in this LCD may be monitored and addressed through post payment data analysis and subsequent medical review audits.
History/Background and/or General Information
Allergen Immunotherapy is defined as the repeated administration of specific allergens to individuals with IgE-mediated conditions to provide protection against allergic symptoms and inflammatory reactions associated with natural exposure to these allergens. 1
Allergen immunotherapy should be considered for patients who have discernable evidence of specific IgE antibodies to clinically relevant allergens. The decision to begin allergen immunotherapy may depend on a number of factors, including but not limited to, patient's preference/acceptability, adherence, medication requirements, response to avoidance methods, and the adverse effects of medications. The severity and duration of symptoms should also be considered when evaluating the need for allergen immunotherapy. 1
The presence of IgE antibodies alone does not infer the need for immunotherapy; the presence of IgE antibodies to an allergen must correlate with the patient’s history. 1 For example, the presence of IgE antibodies to an allergen not locally found, with no history of exposure or expectation of exposure, would not be considered clinically relevant.
In order for allergen immunotherapy to be considered medically reasonable and necessary both of the following criteria must be met:
• The allergen(s) to which the patient is allergic must be clinically relevant, and
• Trial of avoidance measures has failed or there is unavoidable exposure to allergy triggers identified in allergy testing. 1
Covered Indications
Conditions for which immunotherapy will be considered medically reasonable and necessary include:
• Allergic rhinitis
• Allergic conjunctivitis
• Allergic asthma 2-9
• Dust mite atopic dermatitis 1,9-11
• Stinging insect hypersensitivity (e.g., bees, hornets, wasps, fire ants) 1-9
Although all treatment regimens must be individualized for a given patient, immunotherapy generally has two phases. A build-up phase and a maintenance phase .
The build-up phase includes the initiation and subsequent increase of applicable antigen concentrations within 8-28 weeks. Usually a single dose increase is administered per visit and visits generally vary from 1-3 times per week. Accelerated timetables, also referred to as rush or cluster immunotherapy, involve giving several injections at increasing doses on a single visit. 1,9
The maintenance phase occurs when the effective therapeutic dose is reached. This dose provides therapeutic effectiveness without significant adverse local or systemic consequences. This dose may not be the initial targeted concentration/dose. The maintenance immunotherapy schedule is generally every 4-8 weeks for venoms and every 2-4 weeks for inhalant allergens. Maintenance immunotherapy generally involves follow-up visits every 6-12 months. 1,2,9
Length of Maintenance Therapy: The duration of all forms of immunotherapy must be individualized. A presumption of failure can be made when, after 12-24 months of therapy, a person does not experience:
• A noticeable decrease of symptoms,
• An increase in tolerance to the offending allergen, and
• A reduction in medication usage.
For many patients, the recommended duration of allergen immunotherapy is 3-5 years. However, the duration of immunotherapy should be individualized based on the benefits sustained from therapy, disease severity, immunotherapy reaction, patient preference and certain antigens in the therapy. 1,2,9
Desensitization is the rapid administration of incremental doses of allergens or medications by which effector cells are rendered less reactive or nonreactive to an IgE-mediated immune response. Tolerance to medications can be achieved through desensitization. 1
Limitations
• Patients should not have substantial comorbid conditions that could increase immunotherapy risk (e.g., severe asthma uncontrolled by pharmacotherapy, significant cardiovascular disease).
• Patients on beta-blockers and/or angiotensin-converting enzyme (ACE) inhibitor medications must have individualized assessments of risk versus benefit prior to receiving inhalant or venom allergen immunotherapy.
• Patients should be able to cooperate during therapy.
• Please refer to the CMS IOM Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 50.4.4.1 Antigens for additional limitations.
• Please refer to the CMS IOM Publication 100-03, Medicare National Coverage Determinations (NCD) Manual , Chapter 1, Part 2 Sections 110.9 Antigens Prepared for Sublingual Administration and 110.11 Food Allergy Testing and Treatment for additional limitations.
Allergen immunotherapy is not considered medically reasonable and necessary for :
• Food hypersensitivity 1,12-14
• Cockroach hypersensitivity 1
• Urticaria and/or angioedema 1,12,13
• Provocation-neutralization therapy 1,13
• Low-dose subcutaneous therapy based on the Rinkel method 6,12,13
• Therapy formulations, such as allergoids or adjuvants 1
• The following routes of administration 6,12,13 :
• Oral or sublingual for food immunotherapy
• Epicutaneous immunotherapy
• Intralymphatic immunotherapy
• Intranasal immunotherapy
• Sublingual Immunotherapy
• Immunotherapy for Hymenoptera venom sensitivity using whole-body extracts, with the exception of fire ant extracts. 1,2,9
Place of Services (POS)
Immunotherapy may have severe unpredictable systemic and local reactions within the first 30 minutes following the injection. It is recommended that immunotherapy be administered in a setting that permits the prompt recognition and management of adverse reactions, particularly anaphylaxis. It is recommended that patients wait at the physician's office/medical clinic for at least 30 minutes after the immunotherapy injection. 1,6,9
Home administration of allergen immunotherapy should only be considered in rare and exceptional cases when the benefits of immunotherapy clearly outweigh the risks. Frequent or routine home immunotherapy is not considered appropriate under any circumstances. If this method is utilized, informed consent should be attained from the patient and the individual administering the injection must be trained and equipped to recognize and manage immunotherapy reactions, particularly anaphylaxis. 1
Provider Qualifications
Services will be considered medically reasonable and necessary when all aspects of care are within the scope of practice of the provider’s professional licensure, when performed according to the supervision requirements per state scope of practice laws, and when all procedures are performed by appropriately trained providers in the appropriate setting.
Notice: Services performed for any given diagnosis must meet all of the indications and limitations stated in this LCD, the general requirements for medical necessity as stated in CMS payment policy manuals, any and all existing CMS national coverage determinations, and all Medicare payment rules.
Summary of evidence (opening)
A literature search was conducted using the following key words: allergens; allergen immunotherapy; practice guidelines; practice parameters; meta-analysis; systematic review; allergic rhinitis; seasonal allergic rhinitis; allergic conjunctivitis; allergic asthma; inhalant allergies; routes of immunotherapy administration; subcutaneous immunotherapy; allergen-specific immunotherapy, atopic dermatitis; acute and chronic urticaria; skin rash; food allergies; stinging insect allergy; Hymenoptera; anaphylaxis.
Evidence-Based Guidelines
A Joint Task Force represented by the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology (JCAAI) has provided an updated practice parameter for allergen immunotherapy. 1 Also, the European Academy of Allergy and Clinical Immunology (EAACI) and the AAAAI provided an updated, comprehensive consensus report which includes the mechanisms of allergy immunotherapy and its use in clinical practice. 6 In addition, the AAAAI and the ACAAI have provided a practice parameter update for stinging insect hypersensitivity. 2
Allergen immunotherapy is defined as the repeated administration of specific allergens to individuals with IgE-mediated conditions to provide protection against allergic symptoms and inflammatory reactions associated with natural exposure to these allergens. Immunotherapy is effective for pollen, animal allergens, dust mites, mold/fungi, and Hymenoptera hypersensitivity. Allergen immunotherapy should be considered for patients who have discernable evidence of specific IgE antibodies to these allergens. 1
The contractor cites 21 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.
Dates, lineage and related policies
- Original determination effective
- 2018-10-18
- Current revision effective
- 2024-03-31
- MCD version
- 19
The contractor lists 2 National Coverage Determinations as related: NCD 110.11 Food Allergy Testing and Treatment, NCD 110.9 Antigens Prepared for Sublingual Administration. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.
Other related documents: A59575 (Response to Comments).
Using this policy on a claim
Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the First Coast Service Options, Inc. hub lists every other active policy from the same contractor.
The same policy title at other contractors
Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.
For teams evaluating QuickIntell software
Where QuickIntell fits with this policy
If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions
What does LCD L37800 cover?
Allergen Immunotherapy is defined as the repeated administration of specific allergens to individuals with IgE-mediated conditions to provide protection against allergic symptoms and inflammatory reactions associated with natural exposure to these allergens. 1 The full 987-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.
Which states does LCD L37800 apply to?
First Coast Service Options, Inc. applies it to Medicare claims in 1 state plus 2 territories: FL, PR, VI. It binds only that contractor; 1 other contractor version of this title governs other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.
Which diagnosis codes support medical necessity under LCD L37800?
The companion billing and coding article A57678 lists 128 ICD-10-CM codes in 3 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.
How do I appeal a denial under LCD L37800?
A denial under LCD L37800 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A57678's 128 covered diagnosis codes, then file a redetermination with First Coast Service Options, Inc. within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database, current LCD exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file lcd.csvSHA-256 2e0eda3351aa3d47…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.